<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937894</url>
  </required_header>
  <id_info>
    <org_study_id>2021_TIG_001</org_study_id>
    <nct_id>NCT04937894</nct_id>
  </id_info>
  <brief_title>Antibiotic Therapy for Infectious Diseases</brief_title>
  <official_title>The Efficacy and Safety of Tigecycline for the Treatment of Infectious Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tigecycline is a last-resort antibiotic that is used to treat severe infections caused by&#xD;
      extensively drug-resistant bacteria. However, the efficacy and safety data for tigecycline in&#xD;
      infectious patients are lacking. The aim of this study is to assess the efficacy and safety&#xD;
      of tigecycline in infectious patients using pharmacokinetics and omics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Through study completion, an average of 15 days</time_frame>
    <description>Drug-related adverse events and serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of tigecycline</measure>
    <time_frame>Through study completion, an average of 3 days</time_frame>
    <description>clearance in L/h</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate constant for tigecycline distribution</measure>
    <time_frame>Through study completion, an average of 3 days</time_frame>
    <description>Pharmacokinetics of tigecycline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The ratio of area under the concentration-time curve (AUC) to minimum inhibitory concentration (MIC).</measure>
    <time_frame>Through study completion, an average of 3 days</time_frame>
    <description>PD target</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fibrinogen levels in mg/dL</measure>
    <time_frame>Through study completion, an average of 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prothrombin time</measure>
    <time_frame>Through study completion, an average of 3 days</time_frame>
    <description>prothrombin time in second</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>activated partial thromboplastin time</measure>
    <time_frame>Through study completion, an average of 3 days</time_frame>
    <description>activated partial thromboplastin time in second</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>international normalized ratio</measure>
    <time_frame>Through study completion, an average of 3 days</time_frame>
    <description>international normalized ratio，INR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood platelet count</measure>
    <time_frame>Through study completion, an average of 3 days</time_frame>
    <description>blood platelet count in ×10^9/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thrombin time</measure>
    <time_frame>Through study completion, an average of 3 days</time_frame>
    <description>thrombin time in second</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Infectious Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tigecycline</intervention_name>
    <description>Efficacy and safety of Tigecycline</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with severe infections&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  critically ill hospitalized males or nonpregnant females aged 18 years with severe&#xD;
             infections which the treating clinician was treating with tigecycline&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. severe liver dis- eases (e.g., Child-Pugh score C);&#xD;
&#xD;
          2. patients allergic to tetracycline and tigecycline;&#xD;
&#xD;
          3. those who have participated in other clinical trials, or those who are considered&#xD;
             unsuitable by researchers;&#xD;
&#xD;
          4. pregnant women and lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Wei Zhao, Ph.D</last_name>
    <phone>86053188383308</phone>
    <email>zhao4wei2@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wei Zhao</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Zhao, Ph.D</last_name>
      <phone>86053188383308</phone>
      <email>zhao4wei2@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Wei Zhao</investigator_full_name>
    <investigator_title>Head of department of clinical pharmacy and pharmacology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tigecycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

